A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
George R. Blumenschein, Egbert Frederik Smit, David Planchard et al. · Annals of Oncology · 2015
Cited by 349 works. doi:10.1093/annonc/mdv072 Open-access PDF
Authors
- George R. Blumenschein
- Egbert Frederik Smit
- David Planchard
- Jacques L. Cadranel
- Tommaso Martino De Pas
- Frank Dunphy
- Katalin Udud
- Myung‐Ju Ahn
- Nasser H. Hanna
- Ji Hyun Kim
- Julien Mazières
- Sang Wan Kim
- Erica Rappold
- Suman Redhu
- A. Puski
- Frank Shao-Ying Wu
- Pasi Antero Janne
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- Non–Small Cell Lung Cancer
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis